SAGE250117C2500
- 2.60
- 0.000.00%
Sage Therapeutics Newsroom
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Biogen (BIIB.US) plans to acquire the remaining shares of Sage (SAGE.US) at a 30% premium.
Biogen (BIIB.US) will acquire the outstanding shares of Sage Therapeutics (SAGE.US) at a price of $7.22 per share.
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal From Biogen
Express News | Biogen Inc Reports 10.2% Stake in Sage Therapeutics Inc as of Jan 10, 2025
Express News | Biogen Inc - Submits Non-Binding Proposal to Buy All Outstanding Shares of Sage Therapeutics' Common Stock Not Owned by Biogen for $7.22/Share in Cash
Express News | Biogen Inc Says on January 10, Delivered Letter to Sage Therapeutics' CEO - SEC Filing
Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
RBC Raises Price Target on SAGE Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's Is How to Trade
Sage Therapeutics Is Maintained at Overweight by Piper Sandler
Piper Sandler Initiates Sage Therapeutics(SAGE.US) With Buy Rating, Announces Target Price $9
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
As Small-caps Ride the Trump Wave, Here Are the Best & Worst Such Stocks as per SA Quant
Stifel Maintains Hold on Sage Therapeutics, Lowers Price Target to $6
Sage Therapeutics Analyst Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $6
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $10
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Express News | Sage Secures $35 Million in Series B Funding to Transform Senior Living Operations Across the U.S. and Beyond
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference